299. Cystic fibrosis Clinical trials / Disease details


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00743483
(ClinicalTrials.gov)
August 200826/8/2008Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic InsufficiencyAn Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic InsufficiencyCystic Fibrosis;Exocrine Pancreatic InsufficiencyDrug: rhBSSLSwedish Orphan BiovitrumNULLCompleted18 YearsN/AAll15Phase 2Netherlands;Poland
2EUCTR2007-004063-21-NL
(EUCTR)
24/07/200831/10/2007An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/AAn open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A Cystic fibrosis and pancreatic insufficiency
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: rhBSSL
Product Code: rhBSSL
INN or Proposed INN: Bucelipase alfa
Trade Name: Nexium 20
Product Name: Nexium
INN or Proposed INN: Esomeprazole
Biovitrum ABNULLNot RecruitingFemale: yes
Male: yes
18Netherlands